Monoclonal antibody-based therapy of a human tumor xenograft with a super(177)lutetium-labeled immunoconjugate

super(177)Lutetium ( super(177)Lu) is a member of the family of elements known as lanthanides or rare earths. Monoclonal antibody (MAb) CC49, a murine IgG1, which is reactive with the tumor-associated antigen, TAG-72, has been shown previously to react with a wide range of human carcinomas; CC49 rea...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1991-01, Vol.51 (11), p.2889-2896
Main Authors: Schlom, J, Siler, K, Milenic, DE, Eggensperger, D, Colcher, D, Miller, L S, Houchens, D, Cheng, R, Kaplan, D, Goeckeler, W
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:super(177)Lutetium ( super(177)Lu) is a member of the family of elements known as lanthanides or rare earths. Monoclonal antibody (MAb) CC49, a murine IgG1, which is reactive with the tumor-associated antigen, TAG-72, has been shown previously to react with a wide range of human carcinomas; CC49 reacts to a different epitope on the TAG-72 molecule than MAb B72.3 and has a higher binding affinity. We report here the first use of a super(177)Lu-labeled immunoconjugated, super(177)Lu-CC49, in a experimental therapy model for human carcinoma. The merits and limitations of the use of super(177)Lu-labeled immunoconjugates (in particular, super(177)Lu-CC49) are discussed of potential novel therapeutics for human carcinoma.
ISSN:0008-5472